Intuitive Surgical, Inc. · Healthcare
The price already needs more growth than analysts forecast, at both a 9% and an 8% discount rate.
At a 28.0% margin the price requires 21.9% 3y revenue CAGR against 14.6% consensus, a cushion of -21.1pt versus a 0pt correction cut. Price needs more growth than consensus at any nearby discount rate, so the correction has room to go further. Quality-growth multiple; no growth cut.
Would recover if: procedure growth slows after the $450M settlement and sell-the-news reaction. We re-check this against analyst estimates every evening.
10 years, at a 28% margin (analysts' margin, cut for cash conversion)
+9.7%/yr over 10 years once faded to terminal growth
points off 3-year analyst growth
15 published targets
Does the profit analysts build their margin on actually arrive as cash? Measured over the last 3 annual statements filed before this test. After stock-based pay, 74% of reported profit arrived as operating cash, so the test cuts the analysts' 33% margin to 24%. That leaves a cushion of −25pt instead of −17pt, and the smaller of the two decides the group.
How much of reported profit arrived as operating cash. Below 0.8× is a red flag.
Profit not backed by cash, as a share of assets, latest year. Above 10% is a red flag.
Staff paid in shares instead of cash, which flatters margins. Above 10% is a red flag.
Dilution of each share's claim on the business. Above 3% a year is a red flag.
Non-operating gains in the latest year. Above 25% is a red flag.
After capex. Shown for context: heavy investment is not bad earnings, so it is never solved under.
From the priced-in reconstruction of Nov 21, 2026. Its figures use that day's price and free-cash-flow margin, so they can differ from the stress test above.
At the price the market sits 18% below the median published target of $485 and at the 13th percentile of 15 models ($357-$550), meaning the price has heard every bull argument and declines to pay for them, instead pricing the bear case that procedure growth is structurally slowing.
Is US da Vinci procedure growth stable or still decelerating — the single question the 18-point gap between the endorsed models ($391-$415) and the rejected cluster ($475-$550) turns on; segment revenue history can measure quarterly procedure and revenue growth, so this is partially testable with what is wired.
A stress test of whether this narrative is still paid for by analyst forecasts, not a forecast that the stock will rise. The price-implied growth on its own has not predicted returns in our testing, and this list (sealed Nov 21, 2026) has not been graded yet. Cut sizes are assumptions. Not investment advice. Back to all names